MINERALYS THERAPEUTICS

Mineralys Therapeutics Announces Upcoming Poster Presentations at Two Scientific Conferences in November 2023

13 Oct 2023 16:10:31 By Nasdaq GlobeNewswire

Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daphne Karydas

14 Sep 2023 16:05:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics to Participate in the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 28, 2023

11 Sep 2023 16:05:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics Announces JAMA Publication of Full Target-HTN Phase 2 Trial Results for Lorundrostat in Uncontrolled and Treatment-Resistant Hypertension

10 Sep 2023 07:47:12 By Nasdaq GlobeNewswire

Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results in Late-Breaking Science Session at 2023 AHA Hypertension Scientific Sessions

10 Sep 2023 07:45:36 By Nasdaq GlobeNewswire

Mineralys Therapeutics Selected for Oral Poster Presentation of Target-HTN Phase 2 Trial Results at 2023 AHA Hypertension Scientific Sessions

05 Sep 2023 16:05:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics to Participate in the Wells Fargo Securities Healthcare Conference on Thursday, September 7, 2023

29 Aug 2023 16:05:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

07 Aug 2023 16:05:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on Monday, August 7, 2023

31 Jul 2023 16:05:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics Announces Expansion of Planned Phase 2 Trial of Lorundrostat Alone and in Combination with SGLT2 Inhibitor to Treat Patients with Chronic Kidney Disease (CKD)

17 Jul 2023 16:01:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics to Participate in the Jefferies Healthcare Conference

31 May 2023 08:00:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

15 May 2023 16:01:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics Announces First Patient Dosed in the ADVANCE-HTN Pivotal Trial of Lorundrostat for the Treatment of Uncontrolled and Resistant Hypertension

02 May 2023 08:00:02 By Nasdaq GlobeNewswire

Mineralys Therapeutics to Announce First Quarter 2023 Financial Results and Host Conference Call on Monday, May 15, 2023

01 May 2023 08:00:02 By Nasdaq GlobeNewswire

Mineralys Therapeutics to Participate in the Bank of America Securities 2023 Health Care Conference on Wednesday, May 10, 2023

27 Apr 2023 16:47:56 By Nasdaq GlobeNewswire

Mineralys Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

15 Mar 2023 16:01:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC.23/WCC

04 Mar 2023 16:30:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics to Announce Fourth Quarter 2022 Financial Results and Host Conference Call on Wednesday, March 15, 2023

01 Mar 2023 16:05:01 By Nasdaq GlobeNewswire

Mineralys Therapeutics Abstracts Selected to be Presented at the American College of Cardiology Annual Scientific Session & Expo Together with the World Congress of Cardiology (ACC.23/WCC) in March 2023

20 Feb 2023 08:00:00 By Nasdaq GlobeNewswire

Mineralys Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

14 Feb 2023 16:01:00 By Nasdaq GlobeNewswire